<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Am J Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Am J Case Rep</journal-id>
      <journal-id journal-id-type="publisher-id">amjcaserep</journal-id>
      <journal-title-group>
        <journal-title>The American Journal of Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1941-5923</issn>
      <publisher>
        <publisher-name>International Scientific Literature, Inc.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26334783</article-id>
      <article-id pub-id-type="pmc">4562617</article-id>
      <article-id pub-id-type="doi">10.12659/AJCR.894088</article-id>
      <article-id pub-id-type="publisher-id">894088</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin&#x2019;s Lymphoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Alessa</surname>
            <given-names>Mohammed A.</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-amjcaserep-16-590">
            <sup>A</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn2-amjcaserep-16-590">
            <sup>B</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn3-amjcaserep-16-590">
            <sup>C</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-16-590">
            <sup>D</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-16-590">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-16-590">
            <sup>F</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-16-590">
            <sup>1</sup>
          </xref>
          <xref rid="c1-amjcaserep-16-590" ref-type="corresp"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Craig</surname>
            <given-names>Ann Kathryn</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-amjcaserep-16-590">
            <sup>A</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-16-590">
            <sup>D</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cunningham</surname>
            <given-names>James M.</given-names>
          </name>
          <xref ref-type="aff" rid="af2-amjcaserep-16-590">
            <sup>2</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-16-590">
            <sup>D</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-16-590">
            <sup>1</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="af1-amjcaserep-16-590"><label>1</label>Department of Pharmacy, Midtown Medical Center, Columbus Regional Health, Columbus, GA, U.S.A.</aff>
      <aff id="af2-amjcaserep-16-590"><label>2</label>Department of Critical Care, Midtown Medical Center, Columbus Regional Health, Columbus, GA, U.S.A.</aff>
      <author-notes>
        <fn>
          <p>Authors&#x2019; Contribution:</p>
        </fn>
        <fn id="fn1-amjcaserep-16-590">
          <label>A</label>
          <p>Study Design</p>
        </fn>
        <fn id="fn2-amjcaserep-16-590">
          <label>B</label>
          <p>Data Collection</p>
        </fn>
        <fn id="fn3-amjcaserep-16-590">
          <label>C</label>
          <p>Statistical Analysis</p>
        </fn>
        <fn id="fn4-amjcaserep-16-590">
          <label>D</label>
          <p>Data Interpretation</p>
        </fn>
        <fn id="fn5-amjcaserep-16-590">
          <label>E</label>
          <p>Manuscript Preparation</p>
        </fn>
        <fn id="fn6-amjcaserep-16-590">
          <label>F</label>
          <p>Literature Search</p>
        </fn>
        <fn id="fn7-amjcaserep-16-590">
          <label>G</label>
          <p>Funds Collection</p>
        </fn>
        <fn id="fn8-amjcaserep-16-590">
          <p><bold>Conflict of interest:</bold> None declared</p>
        </fn>
        <corresp id="c1-amjcaserep-16-590">Corresponding Author: Mohammed A. Alessa, e-mail: <email>M.alessa84@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>03</day>
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <volume>16</volume>
      <fpage>590</fpage>
      <lpage>593</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>3</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>6</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Am J Case Rep, 2015</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license>
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</license-p>
        </license>
      </permissions>
      <abstract>
        <p>
          <bold>Patient: Male, 74</bold>
        </p>
        <p>
          <bold>Final Diagnosis: Rasburicase-induced methemoglobinemia</bold>
        </p>
        <p>
          <bold>Symptoms: Acute shortness of breath</bold>
        </p>
        <p>
          <bold>Medication: Rasburicase</bold>
        </p>
        <p>
          <bold>Clinical Procedure: Attempted percutaneous coronary intervention (PCI)</bold>
        </p>
        <p>
          <bold>Specialty: Oncology</bold>
        </p>
        <sec>
          <title>Objective:</title>
          <p>
            <bold>Unusual or unexpected effect of treatment</bold>
          </p>
        </sec>
        <sec>
          <title>Background:</title>
          <p>Rasburicase is a recombinant urate oxidase enzyme that converts uric acid to allantoin (an inactive and soluble metabolite that is readily excreted in urine). It is used for the management of tumor lysis syndrome (TLS) in cancer patients receiving chemotherapy. Although rasburicase is a generally safe and effective treatment, it can be associated with the rare and potentially severe complication of methemoglobinemia. Here, we report a case of rasburicase-induced methemoglobinemia in a patient who was diagnosed with aggressive non-Hodgkin&#x2019;s lymphoma.</p>
        </sec>
        <sec>
          <title>Case Report:</title>
          <p>A 74-year-old man with aggressive non-Hodgkin&#x2019;s lymphoma was admitted for initiation of chemotherapy. Upon admission, the patient was found to have hyperkalemia, hyperuricemia, hyperphosphatemia, elevated LDH levels, and acute renal failure. As a result, he was diagnosed with TLS. Rasburicase 6 mg was administered intravenously over a period of 30 min to treat TLS. Later, methemoglobinemia developed, with requirements for oxygen supplementation. Multiple units of packed red blood cells were transfused for recurrent significant anemia secondary to his cancer co-morbidity. The patient was tested for glucose-6 phosphate dehydrogenase (G6PD) deficiency, which returned negative; therefore, methylene blue was considered. After transfusion, the methemoglobin level normalized over the course of a few days, and the oxygen saturation improved without the use of methylene blue. However, during his hospitalization, the patient also developed a pulmonary embolism and had evidence of acute coronary syndrome. Later, the patient died of multiple complications related to his cancer co-morbidity on day 12 of admission.</p>
        </sec>
        <sec>
          <title>Conclusions:</title>
          <p>Blood transfusion and supplemental oxygen, without the use of methylene blue, may be an appropriate therapeutic alternative in rasburicase-induced methemoglobinemia treatment.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>MeSH Keywords</title>
        <kwd>Drug-Related Side Effects and Adverse Reactions</kwd>
        <kwd>Lymphoma, Non-Hodgkin</kwd>
        <kwd>Methemoglobinemia</kwd>
        <kwd>Methylene Blue</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Rasburicase is a recombinant urate oxidase enzyme that converts uric acid to allantoin (an inactive and soluble metabolite that is readily excreted in urine) [<xref rid="b1-amjcaserep-16-590" ref-type="bibr">1</xref>]. It is used for the management of TLS in cancer patients receiving chemotherapy [<xref rid="b1-amjcaserep-16-590" ref-type="bibr">1</xref>]. TLS is a fatal condition that occurs more frequently in patients with hematologic malignancies compared to those with solid tumors [<xref rid="b2-amjcaserep-16-590" ref-type="bibr">2</xref>].</p>
      <p>According to the Guideline for the Management of Pediatric and Adult Tumor Lysis Syndrome, TLS should be treated by aggressive hydration and allopurinol or recombinant urate oxidase (rasburicase) [<xref rid="b2-amjcaserep-16-590" ref-type="bibr">2</xref>]. Although rasburicase is a generally safe and effective treatment, it can be associated with the rare and potentially severe complication of methemoglobinemia [<xref rid="b3-amjcaserep-16-590" ref-type="bibr">3</xref>]. Methemoglobinemia develops when the iron moiety in hemoglobin is oxidized from the ferrous form (Fe<sup>2+</sup>) to the ferric form (Fe<sup>3+</sup>) [<xref rid="b4-amjcaserep-16-590" ref-type="bibr">4</xref>,<xref rid="b5-amjcaserep-16-590" ref-type="bibr">5</xref>]. The ferric form of the iron in the hemoglobin is unable to bind to the oxygen, leading to hypoxia [<xref rid="b4-amjcaserep-16-590" ref-type="bibr">4</xref>,<xref rid="b5-amjcaserep-16-590" ref-type="bibr">5</xref>]. Depending on the methemoglobin levels, the patient may develop cyanosis, hemolysis, altered mental status, tachycardia, acidosis, seizure, coma, or even death (<xref ref-type="table" rid="t1-amjcaserep-16-590">Table 1</xref>) [<xref rid="b5-amjcaserep-16-590" ref-type="bibr">5</xref>,<xref rid="b6-amjcaserep-16-590" ref-type="bibr">6</xref>]. Rasburicase-induced methemoglobinemia has been reported in several cases, often with concurrent glucose-6-phosphate dehydrogenase deficiency [<xref rid="b7-amjcaserep-16-590" ref-type="bibr">7</xref>&#x2013;<xref rid="b13-amjcaserep-16-590" ref-type="bibr">13</xref>]. Glucose-6-phosphate dehydrogenase deficiencyi s considered a risk factor for developing rasburicase-induced methemoglobinemia [<xref rid="b3-amjcaserep-16-590" ref-type="bibr">3</xref>]. Unfortunately, no standard treatment is available for rasburicase-induced methemoglobinemia. Methylene blue (if G6PD deficiency is ruled out) or blood transfusion, in addition to oxygen, has been used for treatment.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 74-year-old African-American male with a height of 175 cm and a weight of 119 kg presented to the oncology outpatient clinic with a rapidly swelling mass in his right jaw and supraclavicular region. A core needle biopsy was performed, which demonstrated an aggressive non-Hodgkin&#x2019;s lymphoma with suspicion for a large B-cell, Burkitt&#x2019;s, or double-hit lymphoma. The patient was admitted to the hospital for initiation of 1 cycle of dose-adjusted EPOCH-R chemotherapy regimen and 1 cycle of intrathecal prophylaxis with methotrexate, cytarabine, and methylprednisolone.</p>
      <p>However, prior to initiation of the chemotherapy, the patient was found to have hyperkalemia, hyperuricemia, hyperphosphatemia, elevated LDH levels, and acute renal failure, for which he was diagnosed with TLS. A single dose of rasburicase 6 mg intravenously over a period of 30 min was administered to treat TLS.</p>
      <p>On the following day, the patient started rituximab but later demonstrated acute shortness of breath and hypoxemia with an oxygen saturation of approximately 70% (<xref ref-type="fig" rid="f1-amjcaserep-16-590">Figure 1</xref>). In addition, the methemoglobin was elevated (10.9%) (<xref ref-type="fig" rid="f2-amjcaserep-16-590">Figure 2</xref>). He responded to supplemental oxygen therapy and further evaluation was done by the medical team. Cardiac enzyme studies showed an elevated troponin value. The patient was taken emergently for cardiac catheterization, which later revealed a small distal right coronary artery lesion, but intervention was not indicated. Shortly thereafter, the patient&#x2019;s oxygen saturation again dropped to approximately 80% and a CT scan showed acute pulmonary emboli within the right lower lobe interlobar pulmonary artery, multiple segmental right lower lobe arteries, and distal middle lobe pulmonary embolism. As a result, the patient was transferred to the intensive care unit with a 100% non-breathing mask.</p>
      <p>The evaluation in the intensive care unit found that the patient had significant methemoglobinemia, which was most likely induced by rasburicase. The G6PD enzyme level was normal. The patient&#x2019;s oxygen saturation remained in the upper 80s, thus the decision was made to initiate a previously ordered blood transfusion first, then consider methylene blue to treat rasburicase-induced methemoglobinemia if refractory. After the blood transfusion, the methemoglobin level dropped to 7.6% and oxygen saturation improved to the low 90s. The methemoglobin levels reduced further to 4.2%, 2.8%, and then to 0.8%, and the oxygen saturation increased to 95%. The methemoglobinemia resolved with blood transfusion and no methylene blue was necessary.</p>
      <p>The patient appeared to be doing relatively well until he developed a suspected aspiration that required full ventilator support, along with renal failure. All chemotherapy was discontinued due to his worsening renal function. The serum creatinine level continued to rise to 5.7 mg/dL and BUN to 151. A right femoral dialysis catheter was inserted and dialysis was recommended by nephrology. Subsequently, the patient developed multi-organ system failure syndrome and he became severely septic. A CT scan of the brain was performed due to the lack of responsiveness of the patient after withdrawal of sedation. The CT scan showed a new hypodense lesion in the posterior aspect of the right internal capsule, with right ventricular system effacement from central nervous system involvement of his non-Hodgkin&#x2019;s lymphoma. De-escalation of advanced life support was pursued by family, with subsequent death.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>TLS is a serious and life-threatening condition that is characterized by hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia due to the abrupt release of cellular components to the bloodstream from rapid cancer cell lysis [<xref rid="b2-amjcaserep-16-590" ref-type="bibr">2</xref>]. This condition is most commonly seen in patients with hematologic malignancies than in those with solid tumors [<xref rid="b2-amjcaserep-16-590" ref-type="bibr">2</xref>]. TLS, if left untreated, may lead to renal failure or even death [<xref rid="b2-amjcaserep-16-590" ref-type="bibr">2</xref>]. The Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome recommend aggressive hydration combined with allopurinol or recombinant urate oxidase (rasburicase) for the treatment of TLS [<xref rid="b2-amjcaserep-16-590" ref-type="bibr">2</xref>]. The recommended rasburicase dose is 0.15&#x2013;0.2 mg/kg daily infused over a period of 30 min and the duration of therapy ranges from 1 to 7 days [<xref rid="b2-amjcaserep-16-590" ref-type="bibr">2</xref>]. Our patient presented with TLS; aggressive hydration was ordered and rasburicase was administered.</p>
      <p>Although rasburicase-induced methemoglobinemia is a rare adverse effect, it could be life-threatening and require immediate management [<xref rid="b3-amjcaserep-16-590" ref-type="bibr">3</xref>]. Methemoglobinemia develops when the iron moiety in hemoglobin is oxidized from the ferrous form (Fe<sup>2+</sup>) to the ferric form (Fe<sup>3+</sup>) [<xref rid="b4-amjcaserep-16-590" ref-type="bibr">4</xref>,<xref rid="b5-amjcaserep-16-590" ref-type="bibr">5</xref>]. The transformation in the iron moiety makes the hemoglobin unable to bind to the oxygen, leading to hypoxia [<xref rid="b4-amjcaserep-16-590" ref-type="bibr">4</xref>,<xref rid="b5-amjcaserep-16-590" ref-type="bibr">5</xref>]. Patients with G6PD deficiency are at higher risk of this rare adverse effect, but it still can occur in patients with normal G6PD enzyme level [<xref rid="b3-amjcaserep-16-590" ref-type="bibr">3</xref>]. In general, it is recommended to use methylene blue in symptomatic patients with a methemoglobin level &gt;20&#x2013;30% [<xref rid="b5-amjcaserep-16-590" ref-type="bibr">5</xref>]. However, methylene blue is not recommended in patients with G6PD deficiency, since it may worsen methemoglobinemia and hemolysis [<xref rid="b14-amjcaserep-16-590" ref-type="bibr">14</xref>].</p>
      <p>In our case, a total of 6 units of packed red blood cells were transfused to correct his pre-existing anemia. His methemoglobin level decreased from 10.6% to 0.8% over 3&#x2013;4 days. Therefore, the addition of methylene blue was not necessary. Many cases of rasburicase-induced methemoglobinemia have been reported in which oxygen, methylene blue, blood transfusion, and/or ascorbic acid were used [<xref rid="b7-amjcaserep-16-590" ref-type="bibr">7</xref>&#x2013;<xref rid="b13-amjcaserep-16-590" ref-type="bibr">13</xref>]. Most of these cases were in patients with G6DP deficiency, but our patient had a normal G6DP enzyme level.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>Rasburicase-induced methemoglobinemia is a rare complication that may occur in patients with normal G6PD enzyme activity. Blood transfusion and appropriate levels of supplemental oxygen may provide sufficient treatment for rasburicase-induced methemoglobinemia without the need for methylene blue. Our patient&#x2019;s death following this reaction was most likely due to the myriad of complications that the patient developed during his hospitalization and underlying cancer co-morbidity.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References:</title>
      <ref id="b1-amjcaserep-16-590">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cairo</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Bishop</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tumour lysis syndrome: new therapeutic strategies and classification</article-title>
          <source>Br J Haematol</source>
          <year>2004</year>
          <volume>127</volume>
          <fpage>3</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">15384972</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-amjcaserep-16-590">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coiffier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Altman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pui</surname>
              <given-names>CH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review</article-title>
          <source>J Clin Oncol</source>
          <year>2008</year>
          <volume>26</volume>
          <fpage>2767</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">18509186</pub-id>
        </element-citation>
      </ref>
      <ref id="b3-amjcaserep-16-590">
        <label>3.</label>
        <element-citation publication-type="webpage">
          <article-title>Sanofi-Aventis. Rasburicase: highlights of prescribing information</article-title>
          <comment><italic><ext-link ext-link-type="uri" xlink:href="http://products.sanofi.us/elitek/elitek.html#section-9">http://products.sanofi.us/elitek/elitek.html#section-9</ext-link></italic>. Accessed December 23, 2014</comment>
        </element-citation>
      </ref>
      <ref id="b4-amjcaserep-16-590">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mansouri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lurie</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Concise review: methemoglobinemia</article-title>
          <source>Am J Hematol</source>
          <year>1993</year>
          <volume>42</volume>
          <fpage>7</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">8416301</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-amjcaserep-16-590">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Umbreit</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Methemoglobin &#x2013; it&#x2019;s not just blue: a concise review</article-title>
          <source>Am J Hematol</source>
          <year>2007</year>
          <volume>82</volume>
          <fpage>134</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">16986127</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-amjcaserep-16-590">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wright</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Lewander</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Woolf</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Methemoglobinemia: etiology, pharmacology, and clinical management</article-title>
          <source>Ann Emerg Med</source>
          <year>1999</year>
          <volume>35</volume>
          <issue>5</issue>
          <fpage>646</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">10533013</pub-id>
        </element-citation>
      </ref>
      <ref id="b7-amjcaserep-16-590">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Browning</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Kruse</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Hemolysis and methemoglobinemia secondary to rasburicase administration</article-title>
          <source>Ann Pharmacother</source>
          <year>2005</year>
          <volume>39</volume>
          <fpage>1932</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">16204390</pub-id>
        </element-citation>
      </ref>
      <ref id="b8-amjcaserep-16-590">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borinstein</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2008</year>
          <volume>50</volume>
          <fpage>189</fpage>
          <pub-id pub-id-type="pmid">17387701</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-amjcaserep-16-590">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ng</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Egelund</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Methemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review</article-title>
          <source>J Oncol Pharm Pract</source>
          <year>2012</year>
          <volume>18</volume>
          <fpage>425</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">22190578</pub-id>
        </element-citation>
      </ref>
      <ref id="b10-amjcaserep-16-590">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ku</surname>
              <given-names>F-C</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>Y-C</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>C-M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rasburicase-induced methemoglobinemia and hemolysis in a patient with malignant lymphoma</article-title>
          <source>J Cancer Res Pract</source>
          <year>2013</year>
          <volume>29</volume>
          <fpage>22</fpage>
          <lpage>27</lpage>
        </element-citation>
      </ref>
      <ref id="b11-amjcaserep-16-590">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bucklin</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Groth</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Mortality following rasburicase-induced methemoglobinemia</article-title>
          <source>Ann Pharmacother</source>
          <year>2013</year>
          <volume>47</volume>
          <fpage>1353</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="pmid">24259700</pub-id>
        </element-citation>
      </ref>
      <ref id="b12-amjcaserep-16-590">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sonbol</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Yadav</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vaidya</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase</article-title>
          <source>Am J Hematol</source>
          <year>2013</year>
          <volume>88</volume>
          <fpage>152</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">22573495</pub-id>
        </element-citation>
      </ref>
      <ref id="b13-amjcaserep-16-590">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roberts</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Freed</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem</article-title>
          <source>Eur J Haematol</source>
          <year>2015</year>
          <volume>94</volume>
          <issue>1</issue>
          <fpage>83</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">24750455</pub-id>
        </element-citation>
      </ref>
      <ref id="b14-amjcaserep-16-590">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosen</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McGehee</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Beutler</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency</article-title>
          <source>Ann Intern Med</source>
          <year>1971</year>
          <volume>75</volume>
          <fpage>83</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="pmid">5091568</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-amjcaserep-16-590" position="float">
      <label>Figure 1.</label>
      <caption>
        <p>Oxygen saturation trending.</p>
      </caption>
      <graphic xlink:href="amjcaserep-16-590-g001"/>
    </fig>
    <fig id="f2-amjcaserep-16-590" position="float">
      <label>Figure 2.</label>
      <caption>
        <p>Methemoglobin level trending.</p>
      </caption>
      <graphic xlink:href="amjcaserep-16-590-g002"/>
    </fig>
    <table-wrap id="t1-amjcaserep-16-590" position="float">
      <label>Table 1.</label>
      <caption>
        <p>Signs and symptoms associated with methemoglobin levels [<xref rid="b5-amjcaserep-16-590" ref-type="bibr">5</xref>,<xref rid="b6-amjcaserep-16-590" ref-type="bibr">6</xref>].</p>
      </caption>
      <table frame="hsides" rules="rows">
        <thead>
          <tr>
            <th align="center" valign="middle" rowspan="1" colspan="1">
              <bold>Methemoglobin levels (%)</bold>
            </th>
            <th align="center" valign="middle" rowspan="1" colspan="1">
              <bold>Signs and symptoms</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">&lt;10%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cyanosis or asymptomatic</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">10&#x2013;20%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cyanosis and/or hemolysis</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">20&#x2013;50%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Mental status changes, headache, fatigue, anxiety, confusion, dizziness, weakness, exercise intolerance, syncope, tachycardia, and/or tachypnea</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">&gt;50%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Metabolic acidosis, seizures, coma, dysrhythmias, or potential death</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
